Premier Research has appointed John Ratliff to the position of Chief Executive Officer and Board member.
 
In this position, he succeeds Ludo Reynders, Ph.D., who will be retiring and will become an advisor to the company and remain a board member.

About John Ratliff

Ratliff brings a wealth of sector experience and achievement to the company, including most recently as CEO and Chairman of Curia, a contract research and development organization. Prior to Curia, Ratliff was CEO of Covance, the drug development business within LabCorp.
 
Ratliff also served in various roles at Quintiles (now IQVIA), a contract research organization, including CFO, COO, President, and board member.
 
“I am pleased to welcome John to Premier — a leading provider of development services to innovators in the pharmaceutical industry. I have the greatest confidence that under his leadership the company will continue to thrive and be a formidable home for our customers, employees, and investors,” said Dr. Reynders.
 
Ratliff commented: “This is a unique opportunity to build on the strong organizational foundations laid by Ludo. I look forward to realizing the full potential of the organization. The combination of our clinical expertise, customer and patient centricity, and fit for purpose technology provides an unmatched opportunity to achieve what we’ve set out to be: a service company that is built for innovation.”

More Premier Research News

Premier Research and BioCentriq, a contract development and manufacturing organization (CDMO), recently entered a strategic partnership to advance the pre-investigational New Drug (IND) process and accelerate the clinical translation of novel cell therapy products.